We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
+29.83%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$2.21B
AUM Growth
+$276M
Cap. Flow
-$34.2M
Cap. Flow %
-1.55%
Top 10 Hldgs %
39.41%
Holding
128
New
23
Increased
32
Reduced
32
Closed
15

Top Buys

Rank Stock Value
1
TRAX
First Tracks Biotherapeutics
TRAX
+$38M
2
ROIV icon
Roivant Sciences
ROIV
+$28.1M
3
AVTX icon
Avalo Therapeutics
AVTX
+$24.6M
4
RVMD icon
Revolution Medicines
RVMD
+$21.9M
5
INSM icon
Insmed
INSM
+$20.6M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$55.6M
2
ACLX
Arcellx
ACLX
+$41.7M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$34.2M
4
TERN
Terns Pharmaceuticals
TERN
+$29.7M
5
APGE icon
Apogee Therapeutics
APGE
+$26.8M

Sector Composition

Rank Sector Weight
1 Healthcare 89.73%
2 Miscellaneous 9.21%
3 Financials 1.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLTE
26
Belite Bio
BLTE
$7.8B
$25.4M 1.15%
165,000
+100,000
+154% +$15.3M
ELVN icon
27
Enliven Therapeutics
ELVN
$4.35B
$25.4M 1.15%
500,000
-86,904
-15% -$3.69M
FBRX
28
DELISTED
Forte Biosciences
FBRX
$24.3M 1.1%
1,145,391
+133,501
+13% +$3.17M
LLY icon
29
CALL
Eli Lilly
LLY
$1.02T
$24M 1.08%
+20,000
New +$20.4M
NRIX icon
30
Nurix Therapeutics
NRIX
$2.71B
$23.5M 1.06%
967,620
– –
ANRO icon
31
Alto Neuroscience
ANRO
$1.4B
$22.4M 1.01%
850,000
+350,000
+70% +$8.09M
MDGL icon
32
Madrigal Pharmaceuticals
MDGL
$12.5B
$21.5M 0.97%
40,000
-15,000
-27% -$7.68M
PTGX icon
33
Protagonist Therapeutics
PTGX
$9.43B
$21.1M 0.95%
172,125
– –
MLYS icon
34
Mineralys Therapeutics
MLYS
$2.49B
$20.2M 0.91%
750,000
– –
RLAY icon
35
Relay Therapeutics
RLAY
$4.17B
$19.6M 0.89%
1,050,000
+650,000
+163% +$9.44M
SGMT icon
36
Sagimet Biosciences
SGMT
$680M
$19.3M 0.87%
2,497,864
+1,629,844
+188% +$11.1M
JBIO
37
Jade Biosciences
JBIO
$1.27B
$18.7M 0.84%
840,350
+200,394
+31% +$4.18M
COGT icon
38
Cogent Biosciences
COGT
$6.03B
$17.4M 0.79%
450,000
-300,000
-40% -$10.5M
TVTX icon
39
Travere Therapeutics
TVTX
$6.15B
$17M 0.77%
300,000
– –
CGEM icon
40
Cullinan Oncology
CGEM
$1.42B
$15.9M 0.72%
875,760
+94,500
+12% +$1.4M
SVRA icon
41
Savara
SVRA
$1.1B
$15.5M 0.7%
2,512,153
– –
IDYA icon
42
IDEAYA Biosciences
IDYA
$3.85B
$14.9M 0.67%
+400,000
New +$12.2M
CATX icon
43
Perspective Therapeutics
CATX
$357M
$14.4M 0.65%
4,214,582
+1,050,000
+33% +$3.97M
ODTX
44
Odyssey Therapeutics
ODTX
$1.38B
$14.3M 0.65%
+766,346
New +$13.4M
OMER icon
45
PUT
Omeros
OMER
$1.37B
$13.4M 0.61%
+1,411,300
New +$16.8M
HLXC
46
Helix Acquisition Corp III
HLXC
$236M
$13.3M 0.6%
1,250,000
– –
EQ icon
47
Equillium
EQ
$140M
$13.1M 0.59%
4,100,000
+2,873,690
+234% +$6.89M
ALKS icon
48
CALL
Alkermes
ALKS
$7.73B
$13.1M 0.59%
+250,000
New +$9.76M
ESTA icon
49
Establishment Labs
ESTA
$2.21B
$12.7M 0.57%
148,013
+48,013
+48% +$3.45M
CLYM
50
Climb Bio
CLYM
$891M
$12.7M 0.57%
972,000
+272,000
+39% +$2.81M
1
2
3 4 5

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q2 2026 Portfolio in Review

As of Q2 2026, Affinity Asset Advisors held 128 positions worth $2.21B, up 14% from $1.94B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Affinity Asset Advisors's Q2 2026 filing shows 23 new, 32 increased, 32 reduced and 15 closed positions. Its largest new stake was First Tracks Biotherapeutics: 2,032,012 shares worth $40.9M. The largest sale was Centessa Pharmaceuticals, an estimated $55.6M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Financials.

  • Affinity Asset Advisors's largest Q2 2026 buy was First Tracks Biotherapeutics: 2,032,012 shares worth $40.9M.
  • Affinity Asset Advisors added most to Roivant Sciences in Q2 2026, an estimated $28.1M increase.
  • Affinity Asset Advisors's biggest Q2 2026 reduction was Teva Pharmaceuticals, cutting an estimated $34.2M.
  • Affinity Asset Advisors fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $55.6M.
  • Affinity Asset Advisors's ten largest holdings make up 39% of its $2.21B portfolio in Q2 2026.
  • Affinity Asset Advisors opened 23 new positions and closed 15 in Q2 2026.
  • Affinity Asset Advisors's portfolio value rose 14% quarter-over-quarter to $2.21B.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.